| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
TKIs have dramatically improved clinical outcomes of the patients with CML-CP. However, even if these patients maintained deep molecular responses, discontinuation of TKI results in early relapse in most cases. Therefore, new therapeutic strategies to eradicate CML stem cells (LSCs) are required to cure CML. We previously identified CD120a, CD225, and CD284 as novel surface molecules on LSCs. Our examination of clinical samples revealed that the detection of these molecules on CD34+CD38- cells might be helpful to evaluate therapeutic effects and to monitor condition changes in CML patients. Also, because TNFα-CD120a-NF-κB signaling promoted LSC proliferation, targeting these molecules may represent an attractive therapeutic approach to eradicate CML stem cells. On the other hands, expression analysis of miRNA which control the level of Abl indicated that epigenetic state of mir-203 promoter was diverse, thereby inducing various expression levels of Bcr/Abl in individual LSCs.
|
